SCORAD随机试验中转移性脊髓压迫8周生存与步行状态的预后因素
SCORAD随机试验纳入686例转移性脊髓压迫患者,比较单次8 Gy与20 Gy分5次放疗,用训练集建立生存Cox模型和8周步行状态logistic模型并在验证集及外部登记数据中验证。男性、肺癌、胃肠癌、其他癌、C1-T12受压、非骨转移和步行状态差与更差总生存显著相关;乳腺癌或前列腺癌原发、步行状态1或2级、膀胱功能正常和既往化疗与8周步行几率增加显著相关。
要点
- 男性、肺癌、胃肠癌、其他癌、C1-T12受压、非骨转移及步行状态差与更差总生存显著相关。
- 乳腺癌或前列腺癌原发、步行状态1或2级、膀胱功能正常及既往化疗与8周步行几率增加显著相关。
- 生存模型ROC AUC在SCORAD验证集为75%(95%CI 69-81),外部登记数据为68%(95%CI 62-74)。
核心结论
- 乳腺癌或前列腺癌原发以及就诊时步行状态良好是生存和治疗后步行的有利预后因素。
研究设计与样本
- SCORAD是一项随机试验,纳入686例患者,比较单次8 Gy放疗与20 Gy分5次放疗。
- 数据分为训练集412例(60%)和验证集274例(40%)。
- 在训练集中用基线因素进行总生存的多变量Cox回归和8周步行状态的logistic回归,并以p≤0.10的后退选择法建立简约模型。
- 在验证集中用受试者工作特征(ROC)分析评估模型预后性能。
- 最终生存模型在另一登记数据集(n=348)中进行验证。
主要发现
- 生存Cox模型识别男性、肺癌、胃肠癌和其他类型癌症、C1-T12受压、存在非骨转移及步行状态差均与更差总生存显著相关(均p<0.05)。
- 所选模型ROC AUC在SCORAD验证集为75%(95%CI 69-81),在外部验证登记数据中为68%(95%CI 62-74)。
- 8周步行结局的logistic模型识别乳腺癌或前列腺癌原发、步行状态1或2级、膀胱功能正常及既往化疗均与8周步行几率增加显著相关(均p<0.05)。
- 所选模型ROC AUC在验证集中为72.3%(95%CI 62.6-82.0)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metastatic spinal cord compression (MSCC) carries a poor prognosis and management is based on the likelihood of maintaining mobility and predicted survival. PATIENTS AND METHOD: SCORAD is a randomised trial of 686 patients comparing a single dose of 8 Gy radiotherapy with 20 Gy in 5 fractions. Data was split into a training set (412, 60%) and a validation set (274, 40%). A multivariable Cox regression for overall survival (OS) and a logistic regression for ambulatory status at 8 weeks were performed in the training set using baseline factors and a backward selection regression to identify a parsimonious model with p ≤ 0.10. Receiver Operating Characteristic (ROC) analysis evaluated model prognostic performance in the validation set. Validation of the final survival model was performed in a separate registry dataset (n = 348). RESULTS: The survival Cox model identified male gender, lung, gastrointestinal, and other types of cancer, compression at C1-T12, presence of non-skeletal metastases and poor ambulatory status all significantly associated with worse OS (all p < 0.05). The ROC AUC for the selected model was 75% (95%CI: 69-81) in the SCORAD validation set and 68% (95%CI: 62-74) in the external validation registry data. The logistic model for ambulatory outcome identified primary tumour breast or prostate, ambulatory status grade 1 or 2, bladder function normal and prior chemotherapy all significantly associated with increased odds of ambulation at 8 weeks (all p < 0.05). The ROC AUC for the selected model was 72.3% (95% CI 62.6-82.0) in the validation set. CONCLUSIONS: Primary breast or prostate cancer, and good ambulatory status at presentation, are favourable prognostic factors for both survival and ambulation after treatment.
引用
- Hoskin PJ, Hopkins K, Misra V, et al. Prognostic factors for survival and ambulatory status at 8 weeks with metastatic spinal cord compression in the SCORAD randomised trial. Radiother Oncol. 2022. PMID: 35618101. doi:10.1016/j.radonc.2022.05.017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。